ArticleThe Annals of pharmacotherapy2026
Efficacy of Continuous Infusions of Furosemide-Albumin Compared With Bumetanide in Critically Ill Patients: A Retrospective Cohort Study.
Article in The Annals of pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous loop diuretics are commonly used for management of fluid overload in critically ill patients; however, diuretic resistance remains a challenge. Comparative data on the efficacy of continuous infusions of bumetanide versus furosemide-albumin in patients requiring diuresis are limited.
objectiveThis study aimed to assess the effects of continuous bumetanide versus continuous albumin-furosemide infusions on urine output in critically ill patients.
methodsThis was a retrospective, single health-system cohort study conducted in critically ill adult patients who received continuous bumetanide or continuous albumin-furosemide infusions for at least 24 hours. The primary endpoint was cumulative urine output at 24 hours after diuretic initiation. Secondary endpoints included total diuretic dose, net fluid balance, total albumin administered, changes in serum creatinine, and serum albumin at 24 hours following diuretic initiation, intensive care unit (ICU) length of stay, and in-hospital mortality.
resultsAmong the 434 patients included, 173 patients received a continuous bumetanide infusion, and 261 patients received a continuous furosemide-albumin infusion. There was no significant difference in urine output at 24 hours between the bumetanide and furosemide-albumin group (3578 mL [1818-4738] vs 3617 mL [2035-4703]; CONCLUSION AND RELEVANCE: This is the first study to evaluate continuous infusions of bumetanide versus furosemide-albumin in critically ill patients requiring diuresis, observing a comparable urine output between diuretics. Findings indicate that bumetanide may be a reasonable alternative in fluid management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.